Bisphosphonate-related osteonecrosis of the jaw after implant placement: a case report and literature review

doi:10.12337/zgkqzzxzz.2021.02.008

Chinese Journal of Oral Implantology ›› 2021, Vol. 26 ›› Issue (1): 35-39.DOI: 10.12337/zgkqzzxzz.2021.02.008

• Original Articles·Typical Case Analysis • Previous Articles Next Articles

Bisphosphonate-related osteonecrosis of the jaw after implant placement: a case report and literature review

Wang Lu^1,2, Lin Haiyan³, Liu Qian^{1,2, 4}, Wang Qian^1,2, Su Yucheng^{2, 4}

¹Beijing Citident Hospital of Stomatology, Beijing 100032, China;
²Beijing Implant Training College(BITC), Beijing 100032, China;
³Savaid Stomatology School, Hangzhou Medical College, Hangzhou 310053，China;
⁴Dental lmplant Center, Peking Union Medical College Hospital, Chinese Academy Of Medical Sciences, Beijing 100032, China

Received:2020-10-04 Online:2021-02-10 Published:2021-06-04
Contact: Su Yucheng, Email: yuchengsu@163.com, Tel: 0086-10-66212299
Supported by:
National Key R&D Program of China(2016YFC1102602）

Abstract

Wang Lu, Lin Haiyan, Liu Qian, Wang Qian, Su Yucheng. Bisphosphonate-related osteonecrosis of the jaw after implant placement: a case report and literature review[J]. Chinese Journal of Oral Implantology, 2021, 26(1): 35-39.

References

[1] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117. DOI: 10. 1016/s0278-2391(03)00720-1.
[2] Favus MJ.Diabetes and the risk of osteonecrosis of the jaw[J]. J Clin Endocrinol Metab, 2007, 92(3):817-818. DOI: 10. 1210/jc. 2007-0098.
[3] Rasmusson L, Abtahi J.Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment[J]. Int J Dent, 2014, 2014:471035. DOI: 10. 1155/2014/471035.
[4] 李俊. 临床药理学. 第4版[M]. 北京:人民卫生出版社,2008, 319.
[5] 刘东刚, 王杰军. 双膦酸盐类药物的发展[J]. 中国肿瘤临床, 2003, 30(9):678-683. DOI: 10. 3969/j. issn. 1000-8179. 2003. 09. 025.
[6] 朱汉民. 双膦酸盐和骨质疏松[J]. 中国实用内科杂志, 2011, 31(7):517-520.
[7] Ruggiero SL, Dodson TB, Assael LA, et al.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl):2-12. DOI: 10. 1016/j. joms. 2009. 01. 009.
[8] Baraldi A, Fusco V, Bellora A, et al.Prevention of bisphosphonates-induced osteonecrosis[J]. Clin Cases Miner Bone Metab, 2007, 4(1):58-61.
[9] Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib[J]. J Bone Miner Metab, 2005, 23 Suppl:36-42. DOI: 10. 1007/BF03026321.
[10] Ficarra G, Beninati F.Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects[J]. Head and Neck Pathology, 2007, 1(2): 132-140. doi: 10. 1007/s12105-007-0033-2. Epub 2007 Dec 5.
[11] Vincenzi B, Santini D, Dicuonzo G, et al.Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients[J]. J Interferon Cytokine Res, 2005, 25(3):144-151. DOI: 10. 1089/jir. 2005. 25. 144.
[12] Wood J, Bonjean K, Ruetz S, et al.Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid[J]. J Pharmacol Exp Ther, 2002, 302(3):1055-1061. DOI: 10. 1124/jpet. 102. 035295.
[13] Bamias A, Kastritis E, Bamia C, et al.Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors[J]. J Clin Oncol, 2005, 23(34):8580-8587. DOI: 10. 1200/JCO. 2005. 02. 8670.
[14] Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates[J]. N Engl J Med, 2005, 353(1):99-102; discussion 99-102. DOI: 10. 1056/NEJM200507073530120.
[15] Palaska PK, Cartsos V, Zavras AI.Bisphosphonates and time to osteonecrosis development[J]. Oncologist, 2009, 14(11):1154-1166. DOI: 10. 1634/theoncologist. 2009-0115.
[16] Masoodi N A.Oral Bisphosphonates and the Risk for Osteonecrosis of the Jaw[J]. British Journal of Medical Practitioners, 2009(2):11-15.
[17] Franco-Pretto E, Pacheco M, Moreno A, et al.Bisphosphonate-induced osteonecrosis of the jaws: clinical, imaging, and histopathology findings[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014, 118(4):408-417. DOI: 10. 1016/j. oooo. 2014. 04. 017.
[18] Badros A, Weikel D, Salama A, et al.Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors[J]. J Clin Oncol, 2006, 24(6):945-952. DOI: 10. 1200/JCO. 2005. 04. 2465.
[19] Surgeons M.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.[J]. J Oral Maxillofac, 2007, 65(3):369-376. DOI: 65(3):369-376. 10. 1016/j. joms. 2006. 11. 003.
[20] Marx RE, Sawatari Y, Fortin M, et al.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment[J]. J Oral Maxillofac Surg, 2005, 63(11):1567-1575. DOI: 10. 1016/j. joms. 2005. 07. 010.
[21] Dimopoulos MA, Kastritis E, Bamia C, et al.Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid[J]. Ann Oncol, 2009, 20(1):117-120. DOI: 10. 1093/annonc/mdn554.
[22] Ripamonti CI, Maniezzo M, Campa T, et al.Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan[J]. Ann Oncol, 2009, 20(1):137-145. DOI: 10. 1093/annonc/mdn526.
[23] Heng C, Badner VM, Vakkas TG, et al.Bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis[J]. Am Fam Physician, 2012, 85(12):1134-1141.
[24] Abtahi J, Agholme F, Aspenberg P.Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model[J]. Int J Oral Maxillofac Surg, 2013, 42(5):632-636. DOI: 10. 1016/j. ijom. 2013. 02. 007.
[25] Khan AA, Sándor GK, Dore E, et al.Bisphosphonate associated osteonecrosis of the jaw[J]. J Rheumatol, 2009, 36(3):478-490. DOI: 10. 3899/jrheum. 080759.
[26] Freiberger JJ.Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl):96-106. DOI: 10. 1016/j. joms. 2008. 12. 003.
[27] Vescovi P, Manfredi M, Merigo E, et al.Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT)[J]. Lasers Med Sci, 2010, 25(1):101-113. DOI: 10. 1007/s10103-009-0687-y.

Bisphosphonate-related osteonecrosis of the jaw after implant placement: a case report and literature review

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics